Immorta Bio Prepares AI Designed SenoMune Peptide for 2026 Clinical Entry

What changed

On 12 October 2026, Immorta Bio announced completion of planned preclinical studies for SenoMune 0257, a synthetic nine amino acid peptide immunotherapy designed to help the immune system recognize and eliminate senescent cells. The Miami based company said it used artificial intelligence to identify the candidate building on prior SenoVax research and is preparing clinical entry in 2026, with initial human evaluation anticipated before year end.

Why it matters

Senescence targeted therapies sit at the intersection of longevity hype and measurable immunology. A company moving from AI designed peptide selection into planned trials gives pharma BD teams a concrete diligence target on whether in silico immunotherapy design is producing IND ready assets, not only platform partnerships.

Who is affected

Longevity and immunotherapy investors must separate platform narrative from the specific SenoMune IND timeline and disclosure quality.

Clinical development leads in oncology and fibrosis adjacent programs should monitor whether senolytic immunotherapies complement or compete with small molecule senolytics in trial design.

AI drug discovery vendors face comparison against a peptide with disclosed amino acid length and a stated clinical entry window.

What to do next

If you track aging biology portfolios, add SenoMune 0257 to your IND watchlist and request public protocol details once filings appear rather than relying on press release efficacy language alone.

What to watch

Watch for clinical trial registry entries, FDA interaction disclosures, and whether Immorta publishes peer reviewed SenoVax follow up data alongside the SenoMune program.

Photo: Pixabay / Pexels

Photo: Pixabay / Pexels

Sources

1. Primary. PR Newswire, Immorta Bio Pioneers AI Designed Senolytic Immunotherapy Targeting Diseases of Aging (12 October 2026). Announces SenoMune 0257 status and clinical timing.
2. Secondary. Immorta Bio corporate disclosures referenced in the release (12 October 2026). Corroborates SenoVax lineage and investigational status disclaimer.